AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32453306
Drug: LCPT 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCPT 2 mg (evening dosing)
Trial: 32453306
Drug: LCPT 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCPT 5 mg (after high-calorie meal)
Trial: 33579715
Drug: Sensor-augmented pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensor-augmented pump therapy with predictive low glucose management (SAP + PLGM)
Trial: 32317724
Drug: Single-molecule real-time
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-molecule real-time sequencing technology
Trial: 34073024
Drug: L-carnitine injection
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-carnitine injection three times weekly
Trial: 34073024
Drug: L-carnitine injection
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-carnitine injection once weekly
Trial: 36124697
Drug: Vaccine-boosted
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine-boosted
Trial: 34219190
Drug: Intravenous hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hypertonic saline (HTS) to achieve and maintain plasma sodium between 145 and 150 mmol/l for 7 days
Trial: 33707305
Drug: SGLT2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitors (SGLT2is)
Trial: 32084280
Drug: YAG vitreolysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YAG vitreolysis treatment
Trial: 35793948
Drug: Overminus lens
RxNorm normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overminus lens therapy
Trial: 35793948
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no overminus lens therapy)
Trial: 32591562
Drug: Palmitoylethanolamide (PEA)
RxNorm normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmitoylethanolamide (PEA) 600 mg, one tablet a day
Trial: 32605614
Drug: stimuli-relevant AATP
RxNorm normalized name: Levant cottonseed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: stimuli-relevant AATP + treatment as usual (TAU)
Trial: 33909188
Drug: Lactobacillus acidophilus
RxNorm normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus acidophilus NCDC15 fermented milk with 8 g of Cichorium intybus root powder (LAC) along with basal diet
Trial: 33909188
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri BFE7 fermented milk with 8 g of Cichorium intybus root powder (LRC) along with basal diet
Trial: 33764198
Drug: Inorganic nitrate
RxNorm normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inorganic nitrate therapy (12 mmol KNO3 capsules)
Trial: 33764198
Drug: Placebo (potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (potassium chloride capsules)
Trial: 34412699
Drug: Passive educational
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive educational intervention (daily rounds, journal clubs, morning reports)
Trial: 32052995
Drug: Stepped care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped care with medication
Trial: 35066899
Drug: Resveratrol (RSV)
DrugBank: Resveratrol (DB02709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (RSV) 1000 mg/day for 8 weeks
Trial: 36072363
Drug: Gardening sessions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gardening sessions (hour-long, twice weekly for two months) with a group donating vegetables to a food pantry
Trial: 36072363
Drug: Gardening sessions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gardening sessions (hour-long, twice weekly for two months) with a group harvesting produce for personal use
Trial: 34517135
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg methylprednisone
Trial: 32029306
Drug: Half-dose prasugrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose prasugrel (30-mg load followed by 5 mg daily)
Trial: 32029306
Drug: Clopidogrel (600-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (600-mg load followed by 75 mg daily)
Trial: 34329567
Drug: Cetagliptin coadministered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetagliptin coadministered with metformin
Trial: 34329567
Drug: Metformin coadministered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin coadministered with cetagliptin
Trial: 32858791
Drug: Cognitive behavioral‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral‐based group therapy
Trial: 32139110
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g of legume-based protein
Trial: 32139110
Drug: 8 g
RxNorm normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g of legume-based protein
Trial: 32139110
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of legume-based protein
Trial: 32139110
Drug: 12 g
RxNorm normalized name: PEG-12 GLYCERYL LAURATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g of legume-based protein
Trial: 35562805
Drug: 5‐methyltetrahydrofolate ≤
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐methyltetrahydrofolate ≤ 10 ng/mL
Trial: 35562805
Drug: 5‐methyltetrahydrofolate ≤
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐methyltetrahydrofolate ≤ 10 ng/mL in genotype CC
Trial: 35562805
Drug: 5‐methyltetrahydrofolate ≤
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐methyltetrahydrofolate ≤ 10 ng/mL in genotype CT
Trial: 35562805
Drug: 5‐methyltetrahydrofolate ≤
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐methyltetrahydrofolate ≤ 10 ng/mL in genotype TT
Trial: 32532275
Drug: UMEC 31.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UMEC 31.25 mcg
Trial: 32368027
Drug: UMEC 62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UMEC 62.5 mcg
Trial: 35157994
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (NTG) plus whole brain radiotherapy (WBRT) (30 Gy in 10 fractions), NTG administered via a transdermal 36 mg patch from Monday to Friday throughout WBRT (10 days)
Trial: 34936265
Drug: Scalp acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scalp acupuncture combined with suspension training
Trial: 33054984
Drug: Audio-visual patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Audio-visual patient information with examples testing a treatment against worms (arm II)
Trial: 32497524
Drug: Low-dose vaccine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vaccine (3·2 × 10^3 per 0·1 mL)
Trial: 32497524
Drug: Medium-dose vaccine
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose vaccine (3·2 × 10^4 per 1 mL)
Trial: 32497524
Drug: High-dose vaccine
RxNorm normalized name: Fluzone 2023-2024 high-dose vaccine Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vaccine (3·2 × 10^5 per 1 mL)
Trial: 33760010
Drug: Intrawound vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrawound vancomycin powder (1000 mg)
Trial: 34939582
Drug: non-rhGH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-rhGH treatment
Trial: 34789638
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplement with whey peptides and branched-chain amino acids
Trial: 36397087
Drug: Letter sent
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letter sent from family doctor to parents informing them of the importance of asthma preventer medication during summer holidays.
Trial: 616186557
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (400 mg cefixime)
Trial: 616186557
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (400 mg cefixime)
Trial: 33496831
Drug: Abaloparatide (ABL),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abaloparatide (ABL), 80 μg
Trial: 33496831
Drug: Teriparatide (TPTD),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (TPTD), 20 μg
Trial: 34596433
Drug: Autologous stem
RxNorm normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous stem cell injection every 3 weeks
Trial: 33144246
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy trials
Trial: 32842270
Drug: Alirocumab (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (75 mg Q2W, with dose up titration to 150 mg Q2W at week 12 if LDL-C ≥1.81 mmol/L at week 8)
Trial: 35976467
Drug: Low-intensity red-light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity red-light (LRL) therapy
Trial: 35976467
Drug: Cessation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation of LRL therapy
Trial: 32227247
Drug: Isradipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (5 mg immediate-release, twice daily for 36 months)
Trial: 35296983
Drug: ISOT (Improving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISOT (Improving the safety of opioid therapy)
Trial: 33382529
Drug: 100 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 × 10^6 CAR+ T-cells (low dose)
Trial: 33382529
Drug: 150 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 × 10^6 CAR+ T-cells (high dose)
Trial: 33382529
Drug: Lymphodepleting chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphodepleting chemotherapy (fludarabine 25 mg/m2 and cyclophosphamide 250 mg/m2 daily × 3)
Trial: 37233875
Drug: Kukoamine B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kukoamine B 0.06 mg/kg
Trial: 37233875
Drug: Kukoamine B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kukoamine B 0.12 mg/kg
Trial: 37233875
Drug: Kukoamine B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kukoamine B 0.24 mg/kg
Trial: 39607505
Drug: Inhaled mannitol
RxNorm normalized name: mannitol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled mannitol
Trial: 32707561
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg·kg body weight‐1)
Trial: 32707561
Drug: Placebo (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (6 mg·kg‐1 dextrose)
Trial: 34617375
Drug: Exenatide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (10 μg) added to insulin therapy
Trial: 33713208
Drug: Cotton (Bt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotton (Bt RCH‐2) exposed to 200 mg/kg soil Cd
Trial: 33713208
Drug: Cotton (Bt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotton (Bt RCH‐2) exposed to 0 mg/kg soil Cd (control)
Trial: 33713208
Drug: Cotton (Bt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotton (Bt RCH‐2) exposed to various higher levels of Cd (200, 400, 600, 800, and 1000 mg/kg soil)
Trial: 32886536
Drug: Mandatory twice‐weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandatory twice‐weekly clinical evaluation
Trial: 32886536
Drug: Standard once‐weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard once‐weekly clinical evaluation
Trial: 33063477
Drug: Aprocitentan 25
RxNorm normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprocitentan 25 mg once daily for 10 days
Trial: 34331766
Drug: Enhanced physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced physical therapy interventions
Trial: 33481341
Drug: Weekly CERA
RxNorm normalized name: CERA
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly CERA administration
Trial: 33481341
Drug: Biweekly CERA
RxNorm normalized name: CERA
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biweekly CERA administration
Trial: 34536278
Drug: Visual Art
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Visual Art Therapy (VAT) - 12 sessions over 6 weeks
Trial: 32665460
Drug: 6-monthly community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-monthly community distribution points (6MCD)
Trial: 36028887
Drug: L-serine (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-serine (3.0 g taken 30 min before bedtime for 2 weeks)
Trial: 36028887
Drug: L-serine
RxNorm normalized name: L-Serine
DrugBank: Serine (DB00133)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-serine
Trial: 36028887
Drug: L-serine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-serine and Placebo
Trial: 34226572
Drug: Rhamnan sulphate
RxNorm normalized name: Potassium sulphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhamnan sulphate (100 mg/day)
Trial: 32859235
Drug: Rifampin combination
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin combination therapy with standard antimicrobial treatment (cloxacillin or vancomycin)
Trial: 32859235
Drug: Standard antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antimicrobial treatment (cloxacillin or vancomycin) without rifampin
Trial: 35803624
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg daily azithromycin
Trial: 34213957
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D3 (170 μg)
Trial: 34213957
Drug: Low-dose vitamin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vitamin D3 (20 μg)
Trial: 33471730
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart (IA)
Trial: 33145864
Drug: 15 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g/day of E. angustifolia fruit powder
Trial: 33145864
Drug: 15 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g/day of isomalt + corn starch (placebo)
Trial: 34592624
Drug: Adjunct yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunct yoga therapy (YG; n = 35)
Trial: 32532144
Drug: Comprehensive intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comprehensive intervention to reduce CVD events including drug therapy, lifestyle changes, and adherence support.
Trial: 32409760
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (Control Group C, n=60)
Trial: 32409760
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (Control Group C)
Trial: 32237945
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (terazosin and nifedipine)
Trial: 34849989
Drug: Denosumab 60
RxNorm normalized name: denosumab 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 60 mg every 6 months for 24 months
Trial: 33260142
Drug: Quinine 1
RxNorm normalized name: quinine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine 1 (25-ml solution, 2 mM of quinine)
Trial: 33260142
Drug: Placebo (25-ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (25-ml sweet-tasting no-carbohydrate solution)
Trial: 33260142
Drug: Control (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (25 ml of water)
Trial: 32108529
Drug: Microdosing LSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microdosing LSD (13 mcg, 11.3% of one tab)
Trial: 32108529
Drug: Microdosing psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microdosing psilocybin (0.3 g of dried psilocybin mushrooms)
Trial: 32751269
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g OBG varying in MW and viscosity
Trial: 32751269
Drug: Control (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (200 mL water alone)
Trial: 38438123
Drug: Rabies control
RxNorm normalized name: rabies virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabies control vaccine
Trial: 33089713
Drug: Active CO2-laser
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active CO2-laser treatment
Trial: 35643855
Drug: Standard-of-care chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care chemotherapy (SoC)
Trial: 35027012
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (60% FiO2 and 0.1 µg/kg PGE1)
Trial: 35027012
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (40% FiO2 and 0.1 µg/kg PGE1)
Trial: 35027012
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (40% FiO2 and 0.2 µg/kg PGE1)
Trial: 32559027
Drug: Dextroamphetamine (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine (2.0 mg/kg, i.p.) in mice
Trial: 32559027
Drug: Dextroamphetamine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine (0.3 mg/kg, p.o.) in humans
Trial: 32559027
Drug: Dextroamphetamine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine (0.3 mg/kg, p.o.)
Trial: 32559027
Drug: mGlu5 expression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mGlu5 expression in drug-naïve mice
Trial: 33471681
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day prednisone for 1 week followed by 1 week of nonsteroidal anti-inflammatory drugs
Trial: 33471681
Drug: 6-week prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-week prednisone therapy
Trial: 33188874
Drug: Utidelone plus
RxNorm normalized name: Utidelone
DrugBank: Utidelone (DB17575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Utidelone plus capecitabine (30 mg/m2 IV daily, days 1-5, over 90 min; capecitabine 1000 mg/m2 orally b.i.d., days 1-14)
Trial: 33188874
Drug: Capecitabine alone
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine alone (1250 mg/m2 orally b.i.d., days 1-14)
Trial: 33129015
Drug: Hormonal treatment
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal treatment + electrotherapy
Trial: 33129015
Drug: Only hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Only hormonal treatment (control)
Trial: 35691208
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for insomnia (CBTi) - 8 weekly group sessions over 3 months
Trial: 33925432
Drug: Saffron extract
RxNorm normalized name: saffron extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron extract (15.5 mg per day)
Trial: 33185990
Drug: Omecamtiv mecarbil
RxNorm normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omecamtiv mecarbil (25 mg, 37.5 mg, or 50 mg twice daily)
Trial: 32183741
Drug: Mirabegron (initially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron (initially 25 mg/day, optional increase to 50 mg/day after week 4/8)
Trial: 32511749
Drug: Alteplase 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase 0.9 mg/kg (maximum 90 mg)
Trial: 35296780
Drug: VV116 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VV116 (oral nucleoside analog)
Trial: 34100746
Drug: Tailor‐made notched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailor‐made notched music therapy
Trial: 32029012
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly sessions of CBT or IPT
Trial: 32029012
Drug: Weekly sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly sessions of CBT or IPT
Trial: 34093551
Drug: Nexvax2 (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nexvax2 (900 μg, n = 12)
Trial: 616191017
Drug: Luseogliflozin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luseogliflozin 2.5 mg once daily for the last 7 days